EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data.

Bell, KJL; Hayen, A; Glasziou, P; Mitchell, AS; Farris, M; Wright, J; Duerr, H-P; Mitchell, P; Irwig, L

EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data.

Bell, KJL Hayen, A

Glasziou, P Mitchell, AS Farris, M Wright, J Duerr, H-P Mitchell, P Irwig, L

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Journal Article
Citation:: Retina (Philadelphia, Pa.), 2017, 37, (3), pp. 509-514
Issue Date:: 2017-03

Closed Access

	Filename	Description	Size
	Ovid_ External Link.pdf	Published version	362.93 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Bell, KJL
dc.contributor.author	Hayen, A https://orcid.org/0000-0003-4046-8030
dc.contributor.author	Glasziou, P
dc.contributor.author	Mitchell, AS
dc.contributor.author	Farris, M
dc.contributor.author	Wright, J
dc.contributor.author	Duerr, H-P
dc.contributor.author	Mitchell, P
dc.contributor.author	Irwig, L
dc.date.accessioned	2022-04-28T00:04:38Z
dc.date.available	2022-04-28T00:04:38Z
dc.date.issued	2017-03
dc.identifier.citation	Retina (Philadelphia, Pa.), 2017, 37, (3), pp. 509-514
dc.identifier.issn	0275-004X
dc.identifier.issn	1539-2864
dc.identifier.uri	http://hdl.handle.net/10453/156721
dc.description.abstract	Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment.The authors used data from 325 participants in the CRUISE study, which included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6 months postrandomization. Analysis of covariance models were fitted to assess clinical validity, and distributions of change were constructed to assess detectability of response.There was no evidence that 1-week CRT, and very strong evidence that 1-week BCVA were associated with baseline-adjusted BCVA at 6 months (P = 0.17 and P < 0.001, respectively). There was strong evidence that both 1-month CRT and 1-month BCVA were associated with baseline-adjusted 6-month BCVA (P = 0.005 and P < 0.001, respectively), but simultaneous adjustment found evidence of independent association only for BCVA (P = 0.71 and P < 0.001 for CRT and BCVA, respectively). Detectability of response tended to be higher for CRT than BCVA at 1 week and 1 month but by 6 months these were equivalent for CRT and BCVA.In this study, BCVA monitoring of treated central retinal vein occlusion patients seemed more informative than time-domain optical coherence tomography monitoring.
dc.format	Print
dc.language	eng
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof	Retina (Philadelphia, Pa.)
dc.relation.isbasedon	10.1097/iae.0000000000001207
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1113 Opthalmology and Optometry
dc.subject.classification	Ophthalmology & Optometry
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Angiogenesis Inhibitors
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Female
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Humans
dc.subject.mesh	Intravitreal Injections
dc.subject.mesh	Macular Edema
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Organ Size
dc.subject.mesh	Predictive Value of Tests
dc.subject.mesh	Ranibizumab
dc.subject.mesh	Retina
dc.subject.mesh	Retinal Vein Occlusion
dc.subject.mesh	Time Factors
dc.subject.mesh	Tomography, Optical Coherence
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Vascular Endothelial Growth Factor A
dc.subject.mesh	Vision Disorders
dc.subject.mesh	Visual Acuity
dc.subject.mesh	Retina
dc.subject.mesh	Humans
dc.subject.mesh	Vision Disorders
dc.subject.mesh	Retinal Vein Occlusion
dc.subject.mesh	Angiogenesis Inhibitors
dc.subject.mesh	Vascular Endothelial Growth Factor A
dc.subject.mesh	Tomography, Optical Coherence
dc.subject.mesh	Organ Size
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Predictive Value of Tests
dc.subject.mesh	Visual Acuity
dc.subject.mesh	Time Factors
dc.subject.mesh	Aged
dc.subject.mesh	Aged, 80 and over
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Macular Edema
dc.subject.mesh	Intravitreal Injections
dc.subject.mesh	Ranibizumab
dc.title	EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB: A Secondary Analysis of Trial Data.
dc.type	Journal Article
utslib.citation.volume	37
utslib.location.activity	United States
utslib.for	1113 Opthalmology and Optometry
utslib.for	1113 Opthalmology and Optometry
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-04-28T00:04:36Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	37
utslib.citation.issue	3

Abstract:

Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion. The authors also assessed detectability of response to treatment.The authors used data from 325 participants in the CRUISE study, which included measurement of time-domain CRT and BCVA at baseline, 1 week, 1 month, and 6 months postrandomization. Analysis of covariance models were fitted to assess clinical validity, and distributions of change were constructed to assess detectability of response.There was no evidence that 1-week CRT, and very strong evidence that 1-week BCVA were associated with baseline-adjusted BCVA at 6 months (P = 0.17 and P < 0.001, respectively). There was strong evidence that both 1-month CRT and 1-month BCVA were associated with baseline-adjusted 6-month BCVA (P = 0.005 and P < 0.001, respectively), but simultaneous adjustment found evidence of independent association only for BCVA (P = 0.71 and P < 0.001 for CRT and BCVA, respectively). Detectability of response tended to be higher for CRT than BCVA at 1 week and 1 month but by 6 months these were equivalent for CRT and BCVA.In this study, BCVA monitoring of treated central retinal vein occlusion patients seemed more informative than time-domain optical coherence tomography monitoring.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/156721